You are here

  • Home
  • Archive
  • Volume 9, Issue 3
  • Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer

Citation Tools

Article menu
Clinical/translational cancer immunotherapy
Original research
Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Ardizzoni A, Azevedo S, Rubio-Viqueira B, et al
Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer
Journal for ImmunoTherapy of Cancer 2021;9:e001865. doi: 10.1136/jitc-2020-001865